Rifampicin is predicted to increase the
metabolism of ergot derivatives, and might therefore be expected to reduce their
efficacy. Note that
rifampicin has been used as a potent
enzyme inducer to reduce ergotamine levels in a patient with ergotism, and was said to play a key role in reducing ergotamine levels.
Monitor the outcome of concurrent use to ensure the effects of
ergot derivatives are adequate.